Monoclonal antibody · Modulator of CD19 and Fc gamma receptor IIB (CD32B) (FCGR2B) · developed by Zenas BioPharma, LLC
Obexelimab is a humanized, Fc-engineered monoclonal antibody that simultaneously binds CD19 and Fc gamma receptor IIB on B cells. By engaging both, it inhibits B-cell receptor signaling and B-cell activity without depleting the cells. It is being studied in warm autoimmune hemolytic anemia and systemic lupus erythematosus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05786573 | Phase 3 | Warm Autoimmune Hemolytic Anemia | Active not recruiting | ZBIO |
| NCT02725515 | Phase 2 | Systemic Lupus Erythematosus | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Warm Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZBIO page.
See ZBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZBIO catalysts and pipeline →